Patrys Ltd (ASX:PAB) CEO Dr James Campbell discusses with Andrew Scott from Proactive the key news that PAT-DX1 meets all specification tests and provides an outline of the next steps towards a clinical trial. He also chats about receiving Victorian Medical Research acceleration funds for PAT-DX1.
Patrys hails successful completion of PAT-DX1 specification testing
